Benefits of a Synbiotic Formula (Synbiotic 2000Forte®) in Critically Ill Trauma Patients: Early Results of a Randomized Controlled Trial
- 782 Downloads
Since probiotics are considered to exert beneficial health effects by enhancing the host’s immune response, we investigated the benefits of a synbiotics treatment on the rate of infections, systemic inflammatory response syndrome (SIRS), severe sepsis, and mortality in critically ill, mechanically ventilated, multiple trauma patients. Length of stay in the intensive care unit (ICU) and number of days under mechanical ventilation were also evaluated.
Sixty-five patients were randomized to receive once daily for 15 days a synbiotic formula (Synbiotic 2000Forte, Medipharm, Sweden) or maltodextrin as placebo. The synbiotic preparation consisted of a combination of four probiotics (1011 CFU each): Pediococcus pentosaceus 5–33:3, Leuconostoc mesenteroides 32–77:1, L. paracasei ssp. paracasei 19; and L. plantarum 2,362; and inulin, oat bran, pectin, and resistant starch as prebiotics. Infections, septic complications, mortality, days under ventilatory support, and days of stay in ICU were recorded.
Synbiotic-treated patients exhibited a significantly reduced rate of infections (P = 0.01), SIRS, severe sepsis (P = 0.02), and mortality. Days of stay in the ICU (P = 0.01) and days under mechanical ventilation were also significantly reduced in relation to placebo (P = 0.001).
The administration of this synbiotic formula in critically ill, mechanically ventilated, multiple trauma patients seems to exert beneficial effects in respect to infection and sepsis rates and to improve the patient’s response, thus reducing the duration of ventilatory support and intensive care treatment.
KeywordsIntensive Care Unit Severe Sepsis Systemic Inflammatory Response Syndrome Intensive Care Unit Stay Resistant Starch
- 11.Pittet D, Thievent B, Wenzel RP, et al. Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Amer Jl Resp Crit Care Med 1996;153:684–693Google Scholar
- 12.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874Google Scholar
- 13.Bone RC, Balk RA, Cerra FB, et al. The ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1656–1662Google Scholar
- 17.American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. Am J Respir Crit Care Med 1996;153:1711–1725Google Scholar
- 26.Gomersall CM. Does the Administration of Lactobacillus to Critically Ill Patients Decrease the Severity of Multi-Organ Dysfunction and Failure? A Pilot Study. London, Roehampton Institute, School of Life Sciences, 1998Google Scholar
- 27.Bengmark S, Martindale R. Prebiotics and synbiotics in clinical medicine. Nutr in Clin Pract 2005;20:244–261Google Scholar